Related Experiment Video
Updated: Nov 1, 2025

Using Chronic Social Stress to Model Postpartum Depression in Lactating Rodents
Published on: June 10, 2013
Agomelatine for postpartum depression and breastfeeding.
1The National Clinical Research Center for Mental Disorders, Beijing Anding Hospital, Capital Medical University, Beijing 100088, China.
Agomelatine effectively treated postpartum depression (PPD) in a breastfeeding mother. This study suggests agomelatine is a safe option for nursing mothers experiencing PPD, with minimal infant exposure due to its short half-life.
Area of Science:
- Psychiatry
- Pharmacology
- Neonatal Medicine
Background:
- Postpartum depression (PPD) poses risks to maternal well-being and infant development.
- Breastfeeding offers significant benefits, necessitating safety data on psychotropic medications for nursing mothers.
- Limited data exists on newer antidepressants, like agomelatine, for PPD treatment during lactation.
More Related Videos
06:39Using a Murine Model of Psychosocial Stress in Pregnancy as a Translationally Relevant Paradigm for Psychiatric Disorders in Mothers and Infants
Published on: June 13, 2021
05:04A Common Marmoset Model of Mother-Infant Intervention for Breastfeeding Disorders in the Presence of Paternal Inhibition and Maternal Neglect
Published on: September 22, 2023
Related Concept Videos
Antidepressant Drugs: MAOIs and Other Agents
Antidepressant Drugs: Overview
Sedatives and Hypnotics Drugs: Miscellaneous Agents
Melatonin congeners like ramelteon (Rozerem) and tasimelteon (Hetlioz) selectively bind to melatonin receptors (MT1 and MT2) and thus mimic the actions of melatonin, a hormone that regulates sleep-wake cycles. Tasimelteon is primarily used for non-24-hour sleep-wake disorder, common in blind patients. They are also used to treat conditions like insomnia...
Antidepressant Drugs: Tricyclics, SSRIs, and SNRIs
G-protein Coupled Receptors
Mania and Antimanic Drugs: Overview